ASBP Aspire-Lakewood Holdings, Inc.
Debt Financing ·
The senior secured revolving credit facility will help fund the cash price for Dura Driver Control Systems, along with cash on hand. The release names no lender.
Nasdaq says Aspire's shares face delisting for missing the $50,000,000 market value rule and the $1.00 bid price rule. The company paid $20,000 to request a hearing, and its 2024 audit carried going-concern doubt.
One letter cites the $50,000,000 market value of listed securities rule, with a deadline of October 13, 2025. The other cites the $1.00 minimum bid price rule.
Aspire Biopharma told the SEC on March 31, 2025 that it needs more time to finish its 2024 financial statements. The notice gives no reason beyond that, and its narrative refers to a 10-Q deadline that does not match the annual report it is about.
The company said it could not file by April 15, 2025, the original due date, because it needs more time for its financial statements.
The lender is an entity controlled by Aspire Biopharma's director of investor relations. $184,543.80 had been loaned as of the filing.
Aspire-Lakewood Holdings, Inc., which operates as Aspire, is an early-stage biopharmaceutical company formed as a Delaware corporation in February 2025. It develops and markets sublingual delivery technology, initially for known drugs. Its lead product is a high-dose sublingual aspirin product, sometimes referred to informally as Instaprin, based on a patent-pending formulation. A clinical trial completed in July 2025 in Florida studied the pharmacokinetics of two aspirin formulations given sublingually and standard oral aspirin. The company says the results will be the backbone of a 505(b)(2) submission to the FDA planned for late 2026. The company contracts with third parties for manufacturing, including Glatt, which produced product for clinical trials, and Microsize, a contract development and manufacturing organization in Quakertown, PA, engaged in January 2026 for the next round of trials of high-dose aspirin for myocardial infarction. The company does not currently have any licensing or collaboration agreements. It is strongly considering licensing its aspirin products and expects to target the heart attack and stroke prevention market through a hospital and specialty care sales force.
| Product or program | What it is | Stage |
|---|---|---|
| High-dose sublingual aspirin (Instaprin) | Aspirin delivered sublingually for faster absorption, targeting heart attack and stroke prevention | Clinical trials completed; 505(b)(2) submission planned for late 2026 |
| Sublingual delivery technology | Patent-pending formulation for rapid sublingual absorption of drugs and nutraceuticals | Patent application filed |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $6,202 | |
| Research and development | $923,914 | $144,356 |
| Net income (loss) | -$24.5 million | -$1.3 million |
| Cash from operations | -$4.9 million | -$265,186 |
| Cash and equivalents | $1.0 million | $3,633 |
Our latest story on this, dated Oct 17, 2025: "Aspire Biopharma Holdings (now Aspire-Lakewood Holdings) seeks Nasdaq hearing on delisting". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 17, 2025: "Aspire Biopharma Holdings (now Aspire-Lakewood Holdings) seeks Nasdaq hearing on delisting". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 18, 2025: "Aspire Biopharma (now Aspire-Lakewood Holdings) gets two Nasdaq deficiency letters". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Dec 26, 2024: "PowerUp Acquisition (now Aspire-Lakewood) gets loan of up to $500,000 before merger". The story links the filing or release it is based on. Read the story.
Aspire-Lakewood Holdings, Inc. trades under the ticker ASBP on NASDAQ.
Aspire-Lakewood Holdings, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Aspire-Lakewood Holdings, Inc. is 1847345. Its filings are on SEC EDGAR.
1,402,557 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Aspire-Lakewood Holdings, Inc. under United States.
Our directory classifies Aspire-Lakewood Holdings, Inc. as: Mixed biopharma / other operations. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Aspire-Lakewood Holdings, Inc. is US7389203057.
aibio.space lists Aspire-Lakewood Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
Aspire-Lakewood Holdings, Inc., which operates as Aspire, is an early-stage biopharmaceutical company formed as a Delaware corporation in February 2025. It develops and markets sublingual delivery technology, initially for known drugs.
High-dose sublingual aspirin (Instaprin): Aspirin delivered sublingually for faster absorption, targeting heart attack and stroke prevention Stage: Clinical trials completed; 505(b)(2) submission planned for late 2026.
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Announced a share repurchase program. SEC Form 8-K (Items 5.03,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a financing. SEC Form 8-K (Items 1.01,5.03,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 3.02,4.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a change of independent auditor. SEC Form 8-K (Items 1.01,2.01,2.03,3.02,3.03,4.01,5.01,5.02,5.03,5.05,5.06,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio